CDK4 and neoplasm: Many previous studies have investigated the role of molecular alterations in the tumor such as pRB, RB1 mutations, CCDN1amplifications, and CCNE1 overexpression as potential biomarkers for CDK4/6i response but these investigations have not yielded any identification of a clinically useful predictive biomarker so far15,30,31.